Latest Commercialization News

EcoGraf has secured a binding term sheet with a major German graphite trader to double its Epanko graphite offtake to 40,000 tpa after five years, underpinning future expansions and project financing.

Klevo Rewards extended its financial services footprint with two acquisitions and proposed a 10:1 share consolidation, while Fly Wallet posted $19 million revenue from an early-stage stablecoin trial in July 2026.

Pathkey.AI has appointed former Altium chairman Sam Weiss as a strategic advisor and raised $2.8 million in a placement led by Weiss, aiming to accelerate its AI-powered chip design platform Chipforge.

Andromeda Metals launches a $3 million Share Purchase Plan to fund the next phase of its High Purity Alumina project, aiming to complete a Pre-Feasibility Study and advance commercialisation.

InFocus Group Holdings has rolled out a major upgrade to its Codexa sweepstakes casino platform, introducing a VIP-style player experience and a proprietary AI-driven compliance engine designed to streamline operations and reduce costs for white-label operators.

Elixir Energy has secured $5 million through a discounted placement to support ongoing flow tests at Lorelle-3H, artificial lift trials at Diona-1, and initiate a strategic review of its Taroom Trough assets.

Prospect Resources reveals significant copper extensions at Nyungu Central, with wide intercepts outside current resource boundaries, while maiden drilling at Sharamba shows promising visual mineralisation.

Almonty Industries posted a striking turnaround in Q2 2026, driven by soaring tungsten prices, ramping Sangdong Mine operations, and a major $800 million convertible notes raise.

RLF AgTech is set to raise $3.9 million through a share placement and convertible notes, aiming to capitalise on recent operational restructuring and accelerate commercial execution in FY27.

Noodlecake Studios, under Streamplay Studio Limited, has secured a publishing agreement with Brazilian developer Mango Salad Games for the PC game Harpooner, marking its entry into Latin America and adding a shorter-cycle title to its portfolio.

Alterity Therapeutics has won a new US composition of matter patent for its lead drug ATH434, extending intellectual property protection to at least 2045 and boosting its commercial potential ahead of Phase 3 trials in Multiple System Atrophy.

Anteris Technologies posted a $51.7 million loss in H1 2026 amid ramped-up R&D and clinical trial activity, supported by a $320 million capital raise and Medicare reimbursement for its DurAVR heart valve trial.